Glenmark Launches Generic Kidney Cancer Drug in US, Targeting ₹4,490 Crore Market

Source: ET Real Estate
Arth Insight · What this means for your wallet
- If you hold Glenmark Pharmaceuticals shares, this US market entry could positively impact the company's revenue and your investment's value.
- This news signals strength in the Indian pharmaceutical sector, potentially influencing the performance of other Indian pharma stocks in your portfolio.
- The generic drug is launched in the US; it won't immediately lower treatment costs for kidney cancer patients in India.
Glenmark Pharmaceuticals Inc. U.S. has launched Axitinib Tablets, a generic version of Pfizer's Inlyta, in the United States for advanced kidney cancer treatment. This strategic move allows Glenmark to tap into a substantial market, with the original drug's annual sales previously reaching approximately ₹4,490 crore (USD 538.4 million) in the US.
- ▸Glenmark Pharmaceuticals has launched a generic version of a kidney cancer drug (Axitinib Tablets) in the US market.
- ▸The generic drug targets the market previously served by Pfizer's Inlyta, which had annual sales of approximately ₹4,490 crore in the US.
- ▸This move reflects Glenmark's strategy to provide affordable medicines and expand its footprint in the significant US pharmaceutical sector.
- ✓Glenmark Pharmaceuticals has launched a generic version of a kidney cancer drug (Axitinib Tablets) in the US market.
- ✓The generic drug targets the market previously served by Pfizer's Inlyta, which had annual sales of approximately ₹4,490 crore in the US.
- ✓This move reflects Glenmark's strategy to provide affordable medicines and expand its footprint in the significant US pharmaceutical sector.
Glenmark Pharmaceuticals Inc. U.S., a subsidiary of the Indian pharmaceutical major Glenmark Pharmaceuticals, has announced the launch of Axitinib Tablets in the United States. These tablets are a generic equivalent of Pfizer's widely used drug, Inlyta, which is prescribed for the treatment of advanced renal cell carcinoma, a type of kidney cancer.
The newly launched Axitinib Tablets are available in two strengths, aiming to provide a more affordable treatment option for patients in the US market. This introduction underscores Glenmark's stated commitment to making essential medicines more accessible and affordable.
Entering a Significant Market Segment
The launch represents a strategic entry for Glenmark into a lucrative and critical healthcare segment. Pfizer's Inlyta tablets recorded annual sales of approximately USD 538.4 million in the United States during the last year. For Indian readers, this translates to a substantial market opportunity of roughly ₹4,490 crore (using an approximate exchange rate of 1 USD = 83.50 INR).
Generic drug launches play a vital role in healthcare by driving down costs and increasing patient access to treatments. For pharmaceutical companies like Glenmark, securing approvals and launching generics in key markets like the U.S. is a crucial part of their growth strategy and contributes significantly to their global revenue.
This development is expected to bolster Glenmark Pharmaceuticals' presence in the highly competitive US pharmaceutical market and contribute to its overall financial performance. Indian investors will be closely watching how this new generic product performs against the branded version and its impact on the company's revenue streams.
This report is for informational purposes only and should not be construed as investment advice.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
What has Glenmark Pharmaceuticals Inc. U.S. launched?
Glenmark Pharmaceuticals Inc. U.S. has launched Axitinib Tablets, which are a generic version of Pfizer's Inlyta, used for treating advanced kidney cancer (renal cell carcinoma).
How large is the market opportunity for this generic drug?
The market for the original drug, Inlyta, in the US recorded annual sales of approximately USD 538.4 million, equivalent to roughly ₹4,490 crore, indicating a significant market opportunity for Glenmark's generic offering.
What does this launch mean for Glenmark Pharmaceuticals?
This launch strengthens Glenmark's presence in the competitive US pharmaceutical market, aligns with its commitment to affordable medicines, and is expected to contribute positively to its revenue and growth strategy.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate

From Chartered Accountant to Fitness Guru: Dinaz Vervatwala's Wellness Journey
Dinaz Vervatwala, founder of Hyderabad's Dinaz's Fitness, transitioned from a chartered accountant to a prominent fitness and wellness coach. Her journey emphasizes holistic wellness, integrating mental health and sustainable practices, inspired by overcoming a personal accident.

Zydus Lifesciences Finalises 50% Joint Venture with Sunshine Healthcare Lanka
Zydus Lifesciences Ltd. has completed its 50:50 joint venture transaction with Sunshine Healthcare Lanka Limited, securing a 50% interest in Zydus Sunshine Lifesciences Pvt Ltd. The partnership was finalised on November 11, 2026, following an extension from its original June 2026 closing date. This strategic move aims to expand Zydus's presence through collaboration.

CCI Clears Advent International's ₹3,150 Crore Investment in Yatharth Hospitals
The Competition Commission of India (CCI) has approved Advent International's substantial ₹3,150 crore investment in Yatharth Hospitals through its affiliate, Rasmalai Limited. This deal will grant Advent a 24.9% minority stake in the healthcare provider. Yatharth Hospitals plans to utilize these funds for its expansion efforts and to enhance its healthcare network, buoyed by strong operational revenues and profit growth.
Related Stories

From Chartered Accountant to Fitness Guru: Dinaz Vervatwala's Wellness Journey
Dinaz Vervatwala, founder of Hyderabad's Dinaz's Fitness, transitioned from a chartered accountant to a prominent fitness and wellness coach. Her journey emphasizes holistic wellness, integrating mental health and sustainable practices, inspired by overcoming a personal accident.

Zydus Lifesciences Finalises 50% Joint Venture with Sunshine Healthcare Lanka
Zydus Lifesciences Ltd. has completed its 50:50 joint venture transaction with Sunshine Healthcare Lanka Limited, securing a 50% interest in Zydus Sunshine Lifesciences Pvt Ltd. The partnership was finalised on November 11, 2026, following an extension from its original June 2026 closing date. This strategic move aims to expand Zydus's presence through collaboration.

CCI Clears Advent International's ₹3,150 Crore Investment in Yatharth Hospitals
The Competition Commission of India (CCI) has approved Advent International's substantial ₹3,150 crore investment in Yatharth Hospitals through its affiliate, Rasmalai Limited. This deal will grant Advent a 24.9% minority stake in the healthcare provider. Yatharth Hospitals plans to utilize these funds for its expansion efforts and to enhance its healthcare network, buoyed by strong operational revenues and profit growth.
BreakingPiramal Pharma Slashes China Reliance to Under 10% for Supply Chain Resilience
Piramal Pharma has significantly reduced its dependence on Chinese raw materials to less than 10%. This strategic move aims to enhance supply chain resilience against geopolitical risks, with the company expanding its manufacturing footprint to India, the UK, and the US.